Patient satisfaction with switching to esomeprazole from existing proton pump inhibitor therapy for gastro-oesophageal reflux disease: An observational, multicentre study

Clinical Drug Investigation

Volumn 29, Issue 12, 2009, Pages 803-810

  Hoogendoorn, Robert J ^a   Groeneveld, Lex ^a   Kwee, J Andy ^a  

^a Huisartsenpraktijk Lupine ^*

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NETHERLANDS; OBSERVATIONAL STUDY; PATIENT SATISFACTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SELF CONCEPT; SYMPTOM; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; OMEPRAZOLE; PATIENT SATISFACTION; PRIMARY HEALTH CARE; PROTON PUMP INHIBITORS; QUESTIONNAIRES; YOUNG ADULT;

EID: 70449409339     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11530810-000000000-00000     Document Type: Article

References (20)

1. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006 Aug; 101 (8): 1900-1920
2. Dent J, El-Serag HB, Wallander MA, et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005 May; 54 (5): 710-719
3. Kulig M, Leodolter A, Vieth M, et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease: an analysis based on the ProGERD initiative. Aliment Pharmacol Ther 2003 Oct; 18 (8): 767-776
4. Shaker R, Castell DO, Schoenfeld PS, et al. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003 Jul; 98 (7): 1487-1493
5. Wiklund I. Review of the quality of life and burden of illness in gastroesophageal reflux disease. Dig Dis 2004; 22 (2): 108-114 (Pubitemid 39274305)
6. Seifert B, Rubin G, de Wit N, et al. The management of common gastrointestinal disorders in general practice: a survey by the European Society for Primary Care Gastroenterology (ESPCG) in six European countries. Dig Liver Dis 2008 Aug; 40 (8): 659-666
7. Jones R, Liker H, Ducrotté P. Symptom prevalence in patients taking over-the-counter and prescribed medication for gastroesophageal reflux disease: results from a multinational survey. Gut 2005; 54 Suppl. VII: A63
8. Kennedy T, Jones R. The prevalence of gastro-oesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms. Aliment Pharmacol Ther 2000 Dec; 14 (12): 1589-1594
9. Rey E, Moreno-Elola-Olaso C, Rodriguez-Artalejo F, et al. Medical consultation for gastro-oesophageal reflux symptoms: reasons and associated factors. Digestion 2004; 70 (3): 173-177
10. Jones R, Armstrong D, Malfertheiner P, et al. Does the treatment of gastroesophageal reflux disease (GERD) meet patients' needs? A survey-based study. CurrMed Res Opin 2006 Apr; 22 (4): 657-662
11. Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the Patient Unmet Needs survey. J Clin Outcomes Manag 2000; 7 (11): 29-34
12. Jones R, Liker HR, Ducrotté P. Relationship between symptoms, subjective well-being and medication use in gastrooesophageal reflux disease. Int J Clin Pract 2007 Aug; 61 (8): 1301-1307
13. Ducrotté P, LikerHR. How do people with gastro-oesophageal reflux disease perceive their disease? Results of amultinational survey. Curr Med Res Opin 2007 Nov; 23 (11): 2857-2865
14. Fass R, ShapiroM,Dekel R, et al. Systematic review: protonpump inhibitor failure in gastro-oesophageal reflux disease: where next? Aliment Pharmacol Ther 2005 Jul; 22 (2): 79-94
15. Miner Jr P,Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003 Dec; 98 (12): 2616-2620
16. Röhss K, Wilder-Smith C, Nauclé r E, et al. Esomeprazole 20 mg provides more effective intragastric acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers. Clin Drug Investig 2004; 24 (1): 1-7
17. Fass R, Sontag SJ, Traxler B, et al. Treatment of patients with persistent heartburn symptoms: a double-blind,randomized trial. Clin Gastroenterol Hepatol 2006 Jan; 4 (1): 50-56
18. Jones R, Patrikios T. The effectiveness of esomeprazole 40mg in patients with persistent symptoms of gastro-oesophageal reflux disease following treatment with a full dose proton pump inhibitor. Int J Clin Pract 2008 Dec; 62 (12): 1844-1850
19. Revicki DA, Crawley JA, Zodet MW, et al. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999 Dec; 13 (12): 1621-1630
20. Wilder-Smith C, Backlund A, Eckerwall G, et al. Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: a randomized, dose-response study. Clin Drug Investig 2008; 28 (6): 333-343